Immuron reports positive clinical study results in the fight against fatty liver disease

Dual-listed early-stage biotech company Immuron (ASX: IMC) has revealed keenly anticipated results for its phase 2 non-alcoholic steatohepatitis (NASH) clinical study. The primary objective of the study was to evaluate the safety and efficacy of IMM-124E.

This category is empty! Please try another category or use our search function to find what you are looking for. If you require further assistance please contact us.